|1.||Huhtaniemi, Ilpo: 5 articles (06/2009 - 05/2003)|
|2.||Hansel, William: 5 articles (07/2008 - 03/2003)|
|3.||Ziecik, Adam J: 5 articles (06/2008 - 05/2003)|
|4.||Rahman, Nafis A: 4 articles (06/2009 - 04/2004)|
|5.||Bodek, Gabriel: 4 articles (06/2005 - 05/2003)|
|6.||Leuschner, Carola: 3 articles (01/2007 - 03/2003)|
|7.||Vuorenoja, Susanna: 2 articles (06/2009 - 06/2008)|
|8.||Toppari, Jorma: 2 articles (06/2009 - 06/2008)|
|9.||Rivero-Müller, Adolfo: 2 articles (06/2008 - 05/2005)|
|10.||Ziecik, A J: 2 articles (04/2007 - 05/2003)|
|1.||Breast Neoplasms (Breast Cancer)
05/01/2003 - "We suggest further development of this novel approach for the treatment of breast cancer by the Hecate-CGbeta for in vivo trials."
03/01/2003 - "The ability of hecate-betaCG to destroy xenografts of human breast cancer cells (MDA-MB-435S) in nude mice was demonstrated for the first time. "
05/01/2003 - "To test the hypothesis that the Hecate-CGbeta conjugate selectively abolishes cells possessing LHR, estrogen dependent and independent human breast cancer cell lines (MCF-7; MDA-MB-231) and a mouse Leydig tumor cell line (BLT-1) were treated in vitro with Hecate-CGbeta conjugate and Hecate alone. "
03/01/2003 - "We conclude that hecate-betaCG and LHRH-hecate conjugates could serve as useful drugs for the treatment of breast cancer."
03/01/2003 - "Hecate, hecate-betaCG and LHRH-hecate were added to cultures of the human breast cancer cell lines MCF-7 and MDA-MB-435S. "
06/01/2008 - "Hereby, our findings support the principle that Hecate-CGbeta conjugate is able to specifically destroy tumor cells that ectopically express LHR."
06/01/2008 - "This finding provides evidence for a selective destruction of the tumor cells by the Hecate-CGbeta conjugate. "
06/01/2008 - "The Hecate-CGbeta conjugate reduced the adrenal tumor burden significantly in TG male but not in female mice, in comparison with Hecate-treated mice. "
06/01/2008 - "Wild-type control littermates and TG mice with adrenal tumors were treated with either Hecate or Hecate-CGbeta conjugate at the age of 6.5 months for 3 weeks and killed 7 days after the last treatment. "
05/01/2005 - "These results prove the principle that the Hecate-CGbeta conjugate provides a novel specific lead into gonadal somatic cell cancer therapy by targeted destruction of LHR-expressing tumor cells."
|3.||Granulosa Cell Tumor
11/01/2005 - "Hecate-betaCG was less effective in mice bearing ovarian epithelial cancer cell xenografts, but was highly effective in treating granulosa cell tumors in transgenic mice. "
05/01/2005 - "Transgenic (TG) mice expressing the inhibin alpha-subunit promoter (inhalpha)/Simian Virus 40 T-antigen (Tag) transgene, developing luteinizing hormone (LH) receptor (R) expressing Leydig and granulosa cell tumors, and wild-type control littermates were treated either with vehicle, Hecate, or Hecate-CGbeta conjugate for 3 weeks. "
|4.||Neoplasm Metastasis (Metastasis)
06/01/2005 - "Targeted ablation of prostate carcinoma cells through LH receptor using Hecate-CGbeta conjugate: functional characteristic and molecular mechanism of cell death pathway."
05/01/2003 - "A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate."
04/01/2004 - "Recently, we have shown that Hecate-CGbeta conjugate, which is a fusion of the lytic peptide Hecate and a 15-amino acid fragment of the beta-chain of chorionic gonadotropin (CGbeta), selectively destroys mammary gland carcinoma cells that possess luteinizing hormone receptors (LHR) in vitro. "
|1.||Ovarian epithelial cancer
|2.||LH Receptors (LH Receptor)
|3.||Chorionic Gonadotropin (Human Chorionic Gonadotropin)
|4.||Tumor Viral Antigens (Large T Antigen)
|6.||Luteinizing Hormone (Lutropin)
|9.||Messenger RNA (mRNA)
|1.||Heterologous Transplantation (Xenotransplantation)